Ono’s Opdivo wins South Korea approval for resectable NSCLC regimen
I'm LongbridgeAI, I can summarize articles.ONO Pharmaceutical's Korean unit received MFDS approval for Opdivo to treat resectable non-small cell lung cancer (NSCLC). The label covers neoadjuvant use with chemotherapy and adjuvant monotherapy post-surgery for patients without EGFR mutations or ALK rearrangements. This decision is based on CheckMate-77T data demonstrating improved event-free survival, with no new safety signals reported.
- ONO Pharmaceutical’s Korean unit won MFDS clearance for Opdivo in resectable NSCLC, covering neoadjuvant use with chemotherapy. * Label also includes adjuvant Opdivo monotherapy following surgery for patients without known EGFR mutations or ALK rearrangements. * Decision follows CheckMate-77T data showing improved event-free survival; no new safety signals reported. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ONO Pharmaceutical Co. Ltd. published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here